中基健康(000972) - 2025 Q3 - 季度财报

Financial Performance - The company's operating revenue for the current period is ¥109,239,299.24, representing a year-on-year increase of 107.32%[5] - The net profit attributable to shareholders of the listed company is -¥68,229,862.97, with a year-to-date net profit of -¥144,087,480.95[5] - Total operating revenue for the current period reached CNY 354,172,619.51, an increase of 19% compared to CNY 297,820,015.92 in the previous period[20] - Net loss for the current period was CNY -150,986,842.99, compared to a net loss of CNY -42,913,551.68 in the previous period, reflecting a significant decline in profitability[21] - The company reported a basic and diluted earnings per share of CNY -0.1868, compared to CNY -0.0565 in the previous period[21] Assets and Liabilities - The total assets at the end of the reporting period amount to ¥1,248,281,653.41, a decrease of 28.24% compared to the end of the previous year[5] - The company's total assets decreased to CNY 1,248,281,653.41 from CNY 1,739,625,960.93 in the previous period, reflecting a significant contraction in asset base[18] - Total liabilities amounted to CNY 1,415,955,682.45, down from CNY 1,756,688,135.47 in the previous period, indicating a reduction in overall debt[18] - The company's equity attributable to shareholders was reported at CNY -171,455,526.61, a decline from CNY -27,368,045.66 in the previous period[19] Cash Flow - The cash flow from operating activities for the year-to-date is -¥37,369,039.83[5] - Cash flow from operating activities decreased to CNY 262,907,647.90, down from CNY 380,194,887.13 in the previous period, indicating a decline in cash generation[22] - Net cash flow from operating activities was -$37.37 million, compared to -$12.08 million in the previous period, indicating a decline in operational cash generation[23] - Total cash inflow from financing activities was $219.08 million, down from $501.93 million in the previous period, reflecting a significant decrease in financing[23] Inventory and Expenses - The company’s inventory decreased by 44.48% to ¥546,062,861.72, primarily due to increased sales of large barrel sauce[8] - Total operating costs increased to CNY 484,958,167.04, up 55.5% from CNY 311,484,738.21 in the previous period[20] - The company’s financial expenses increased by 60.30% to ¥32,815,847.47, mainly due to higher interest expenses on bank loans[9] Strategic Changes - The company has initiated a pre-restructuring process with the Xinjiang Production and Construction Corps Sixth Division Intermediate People's Court, indicating potential strategic changes ahead[13] - A restructuring investment agreement was signed with multiple financial investors, which may influence future capital structure and operational strategies[14] - The company is actively seeking restructuring investors to enhance its financial stability and operational efficiency[13] - The company’s total liabilities and equity structure will be reassessed as part of the restructuring process, which may lead to significant changes in financial strategy[14]